These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 25219591)

  • 1. Does the presence of hepatitis virus B and C influence the evolution of diffuse large B-cell lymphoma?
    Rubio J; Franco F; Sánchez A; Cantos B; Méndez M; Calvo V; Maximiano C; Perez D; Millán I; Sánchez-Beato M; Provencio M
    Leuk Lymphoma; 2015 Jun; 56(6):1686-90. PubMed ID: 25219591
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatitis B virus-associated diffuse large B-cell lymphoma: unique clinical features, poor outcome, and hepatitis B surface antigen-driven origin.
    Deng L; Song Y; Young KH; Hu S; Ding N; Song W; Li X; Shi Y; Huang H; Liu W; Zheng W; Wang X; Xie Y; Lin N; Tu M; Ping L; Ying Z; Zhang C; Sun Y; Zhu J
    Oncotarget; 2015 Sep; 6(28):25061-73. PubMed ID: 26314957
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does hepatitis C virus affect the reactivation of hepatitis B virus following renal transplantation?
    Yen TH; Huang CC; Lin HH; Huang JY; Tian YC; Yang CW; Wu MS; Fang JT; Yu CC; Chiang YJ; Chu SH
    Nephrol Dial Transplant; 2006 Apr; 21(4):1046-52. PubMed ID: 16390851
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low incidence of hepatitis B virus reactivation during chemotherapy among diffuse large B-cell lymphoma patients who are HBsAg-negative/ HBcAb-positive: a multicenter retrospective study.
    Ji D; Cao J; Hong X; Li J; Wang J; Chen F; Wang C; Zou S
    Eur J Haematol; 2010 Sep; 85(3):243-50. PubMed ID: 20491883
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Splenic large B-cell lymphoma in patients with hepatitis C virus infection.
    Takeshita M; Sakai H; Okamura S; Oshiro Y; Higaki K; Nakashima O; Uike N; Yamamoto I; Kinjo M; Matsubara F
    Hum Pathol; 2005 Aug; 36(8):878-85. PubMed ID: 16112004
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of hepatitis B virus, hepatitis C virus, and human immunodeficiency virus seroprevalence in patients with diffuse large B cell lymphoma and Hodgkin's lymphoma.
    Mert D; Merdin A; Ceken S; Dal MS; Ertek M; Altuntas F
    J Cancer Res Ther; 2021; 17(4):951-955. PubMed ID: 34528547
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of treatment-related toxicity on outcome of HCV-positive diffuse large B-cell lymphoma in rituximab era.
    Zaky AH; Bakry R; El-sayed MI; Elwanis MA; Nabih O
    Hematology; 2014 Oct; 19(7):412-6. PubMed ID: 24620947
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatitis B virus reactivation after withdrawal of prophylactic antiviral therapy in patients with diffuse large B cell lymphoma.
    Liu WP; Wang XP; Zheng W; Ping LY; Zhang C; Wang GQ; Song YQ; Zhu J
    Leuk Lymphoma; 2016; 57(6):1355-62. PubMed ID: 26727044
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Investigation of hepatitis B and hepatitis C virus infections by serological and molecular methods in hemodialysis patients].
    Dağlar D; Ergani A; Demirbakan H; Ozhak Baysan B; Ongüt G; Koçak H; Oğünç D; Akbaş H; Yıldırım B; Colak D
    Mikrobiyol Bul; 2014 Jan; 48(1):143-50. PubMed ID: 24506725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatitis B virus and hepatitis C virus infection among HIV-1-infected injection drug users in Dali, China: prevalence and infection status in a cross-sectional study.
    Dong Y; Qiu C; Xia X; Wang J; Zhang H; Zhang X; Xu J
    Arch Virol; 2015 Apr; 160(4):929-36. PubMed ID: 25616842
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinico-biological characteristics and outcome of hepatitis C virus-positive patients with diffuse large B-cell lymphoma treated with immunochemotherapy.
    Dlouhy I; Torrente MÁ; Lens S; Rovira J; Magnano L; Giné E; Delgado J; Balagué O; Martínez A; Campo E; Forns X; Sánchez-Tapias JM; López-Guillermo A
    Ann Hematol; 2017 Mar; 96(3):405-410. PubMed ID: 28035434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The NOTCH pathway is recurrently mutated in diffuse large B-cell lymphoma associated with hepatitis C virus infection.
    Arcaini L; Rossi D; Lucioni M; Nicola M; Bruscaggin A; Fiaccadori V; Riboni R; Ramponi A; Ferretti VV; Cresta S; Casaluci GM; Bonfichi M; Gotti M; Merli M; Maffi A; Arra M; Varettoni M; Rattotti S; Morello L; Guerrera ML; Sciarra R; Gaidano G; Cazzola M; Paulli M
    Haematologica; 2015 Feb; 100(2):246-52. PubMed ID: 25381127
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lymphocyte/monocyte ratio and cycles of rituximab-containing therapy are risk factors for hepatitis B virus reactivation in patients with diffuse large B-cell lymphoma and resolved hepatitis B.
    Wu CY; Hsiao LT; Chiou TJ; Gau JP; Liu JH; Yu YB; Wu YT; Liu CJ; Huang YC; Hung MH; Chen PM; Huang YH; Tzeng CH
    Leuk Lymphoma; 2015; 56(8):2357-64. PubMed ID: 25459444
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinicopathologic characteristics and outcomes of transformed diffuse large B-cell lymphoma in hepatitis C virus-infected patients.
    Hosry J; Miranda RN; Samaniego F; Economides MP; Torres HA
    Int J Cancer; 2018 Mar; 142(5):940-948. PubMed ID: 29047108
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and prognosis of antiviral therapy on hepatitis C following treatment of lymphoma in HCV-positive diffuse large-cell lymphoma.
    Tsutsumi Y; Nakayama C; Kamada K; Kikuchi R; Kudo D; Ito S; Matsuoka S; Shiratori S; Yamamoto Y; Naruse H; Teshima T
    Ann Hematol; 2017 Dec; 96(12):2057-2061. PubMed ID: 28939993
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatitis C virus and diffuse large B-cell lymphoma: Pathogenesis, behavior and treatment.
    Visco C; Finotto S
    World J Gastroenterol; 2014 Aug; 20(32):11054-61. PubMed ID: 25170194
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatitis C Virus Infection and Treatment as Independent Prognostic Factors in Diffuse Large B-Cell Lymphoma Egyptian Patients.
    Elbedewy TA; Elashtokhy HEA; Abd-Elsalam S; Suliman MA
    Curr Cancer Drug Targets; 2020; 20(8):638-645. PubMed ID: 32392114
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Long-term results of HBV and HCV infection in patients with blood system diseases].
    Garmaeva TTs; Kulikov SM; Mikhaĭlova EA; Gemdzhian EG; Gaponova TV; Grumbkova LO; Iaroslavtseva NG; Tupoleva TA; Somova AV; Makarik TA; Glinshchikova OA; Fevraleva IS; Sudarikov AB; Filatov FP; Savchenko VG
    Ter Arkh; 2011; 83(7):17-26. PubMed ID: 21894747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatitis B and C serologic profiles of Canadian organ donors and recipients: retrospective 10-year review at a single center.
    Burton CE; Doucette KE; Mabilangan CA; Plitt SS; Lee BE; Preiksaitis JK
    Transpl Infect Dis; 2016 Aug; 18(4):520-8. PubMed ID: 27226204
    [TBL] [Abstract][Full Text] [Related]  

  • 20. microRNA levels in paraffin-embedded indolent B-cell non-Hodgkin lymphoma tissues from patients chronically infected with hepatitis B or C virus.
    Bruni R; Marcantonio C; Pulsoni A; Tataseo P; De Angelis F; Spada E; Marcucci F; Panfilio S; Bianco P; Riminucci M; Villano U; Tosti M; Ciccaglione A; Mele A
    BMC Infect Dis; 2014; 14 Suppl 5(Suppl 5):S6. PubMed ID: 25236768
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.